(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Oil, energy and food: Which countries in Europe are most exposed to higher food prices?- Pick Your #1 Kind Of Bread
- Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- Sexual violence is being used as a weapon in Sudan's war, doctors group says
- Governments take targeted action as fuel prices hit retail
- The Appearance of Experience: Embracing the Reduced Portage Horse
- Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- California officials warn against foraging wild mushrooms after deadly poisoning outbreak
